In this Revenue Search episode, the hosts sit down with Aldo from Subnet 55 (NIOME / “Neural Intelligence in Omics”)—a project tackling one of the messiest problems in biotech: how to make genomic/biodata usable for research and AI without turning it into a privacy and cybersecurity nightmare. Aldo walks through why the status quo is broken, pointing to repeated breaches and misuse across the industry (from direct-to-consumer testing firms to major institutions), and makes the case that “compliance” doesn’t equal “security” when hackers are actively targeting sensitive health data.
NIOME’s approach is twofold. First, through the wider genomes.io ecosystem, individuals can store their DNA data in encrypted “vaults” where the user remains the owner and controls access—rather than handing away rights to hospitals or platforms. Second, the subnet’s core mission is to generate synthetic genomic / biodata at scale—so pharma, biotech, and researchers can train models and run analyses without exposing raw identifiable datasets. The roadmap is built around a structured series of predictive challenges (starting with cystic fibrosis / CFTR), with commercial interest already forming around bespoke challenges, licensing outputs, and data brokerage partnerships (e.g., bringing external datasets into the synthetic pipeline and sharing revenue when that data is used). The big idea: make biodata safe, precise, and scalable and use Bittensor’s open, inspectable “under-the-hood” model development to build trust versus black-box approaches.
